Product
Gemcitabine + Cisplatin + Tislelizumab
1 clinical trial
1 indication
Indication
Hodgkin lymphomaClinical trial
Tislelizumab Plus Gemcitabine and Cisplatin for Relapsed or Refractory Hodgkin Lymphoma Followed by Tislelizumab Consolidation in Patients in Metabolic Complete Remission (TIGERR-HL). An Open Label Phase II TrialStatus: Recruiting, Estimated PCD: 2027-04-01